French Fine-Chemicals Company Provence Technologies Acquires SynprosisBy
Provence Technologies Group, a specialist fine-chemistry research group based in Marseille, France, has acquired Synprosis, a company specialized in the chemical synthesis of peptides and proteins for therapeutic use. Synprosis is based in Aix-en-Provence, France. The financial terms of the agreement were not disclosed.
The deal opens up new development opportunities for the Provence Technologies Group in the area of biologically active pharmaceuticals. Synprosis has a 10-year history of producing actives for vaccines under development (for malaria, cancer, and allergies) as well as in other therapeutic fields (for neurogenerative diseases and the treatment of pain). The company was first recognized for its expertise in creating synthetic vaccines for HIV and malaria. The technology developed by Synprosis offers increased peptide production yields, according to a statement by Provence Technologies.
The Group's new entity has adopted the name Provepep. Synprosis will be the division specialized in pharmaceutical standard production. Jean-Pierre Salles, who founded Synprosis, will remain in the Provepep executive management team.
Provence Technologies is an independent company offering R&D services to the pharmaceutical, biopharmaceutical, agrochemical and cosmetic industries in the area of fine chemistry, including research into synthesis pathways, synthesis of organic compounds, chemical development, and process optimization. Provence Technologies also provides services in the development and validation of analytical methods.
Source: Provence Technologies